Profound Medical Corp
TSX:PRN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Profound Medical Corp
TSX:PRN
|
CA |
|
Viva Goods Co Ltd
HKEX:933
|
HK |
|
Invinity Energy Systems PLC
F:A10
|
UK |
|
S
|
Stora Enso Oyj
OMXH:STERV
|
FI |
|
E
|
Ege Endustri ve Ticaret AS
IST:EGEEN.E
|
TR |
|
AltaGas Ltd
TSX:ALA
|
CA |
|
Projektengagemang Sweden AB
STO:PENG B
|
SE |
|
D
|
DIT Group Ltd
HKEX:726
|
HK |
|
A
|
Airea PLC
LSE:AIEA
|
UK |
|
Achieve Life Sciences Inc
NASDAQ:ACHV
|
US |
|
S
|
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
|
CN |
|
SFC Energy AG
XETRA:F3C
|
DE |
|
Hershey Creamery Co
OTC:HRCR
|
US |
|
Ginlong Technologies Co Ltd
SZSE:300763
|
CN |
|
D
|
Dundas Minerals Ltd
ASX:DUN
|
AU |
|
Cloudflare Inc
NYSE:NET
|
US |
|
I
|
Inuvo Inc
AMEX:INUV
|
US |
|
Compania de Distribucion Integral Logista Holdings SA
MAD:LOG
|
ES |
|
L
|
Lucas GC Ltd
NASDAQ:LGCL
|
CN |
|
Chongqing Zaisheng Technology Co Ltd
SSE:603601
|
CN |
|
Loblaw Companies Ltd
TSX:L
|
CA |
|
M
|
Maxicity Holdings Ltd
HKEX:2295
|
HK |
Profound Medical Corp
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
